METHODS OF MODULATING TETRABENAZINE METABOLITES PLASMA LEVELS USING BUPROPION
This disclosure relates to methods administering bupropion, such as S-bupropion or R-bupropion, in conjunction with tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine to a human being. Dosage forms, drug delivery systems, and methods related to tetrabenazine, alpha-dihydrotetrabenazine, or beta-dihydrotetrabenazine and bupropion, such as S-bupropion or R-bupropion, are also disclosed.
1 . A method of treating tardive dyskinesia, comprising administering a therapeutically effective amount of bupropion to a human being daily for at least 8 consecutive days, and wherein the bupropion has an enantiomer excess of at least 90% of S-bupropion.
2 . The method of claim 1 , wherein the bupropion is administered to the human being once a day for 1, 2, 3 or 4 days, then administered twice a day for 4, 5, 6, 7, or more days.
3 . The method of claim 1 , wherein a daily dose of the bupropion is about 50 mg to about 100 mg.
4 . The method of claim 1 , wherein a daily dose of the bupropion is about 100 mg to about 150 mg.
5 . The method of claim 1 , wherein a daily dose of the bupropion is about 150 mg to about 200 mg.
6 . The method of claim 1 , wherein a daily dose of the bupropion is about 200 mg to about 250 mg.
7 . The method of claim 1 , wherein a daily dose of the bupropion is about 250 mg to about 300 mg.
8 . The method of claim 1 , wherein a daily dose of the bupropion is about 300 mg to about 400 mg.
9 . The method of claim 1 , wherein administering the therapeutically effective amount of the bupropion has a therapeutic effect that is greater than would result from administering a placebo.
10 . The method of claim 1 , wherein the human being has a history of being treated with chlorpromazine.
11 . The method of claim 1 , wherein the human being has a history of being treated with fluphenazine.
12 . The method of claim 1 , wherein the human being has a history of being treated with haloperidol.
13 . The method of claim 1 , wherein the human being has a history of being treated with pephenazine.
14 . The method of claim 1 , wherein the human being has a history of being treated with risperidone.
15 . The method of claim 1 , wherein the human being has a history of being treated with paliperidone.
16 . The method of claim 1 , wherein the human being has a history of being treated with aripiprazole.
17 . The method of claim 1 , wherein the human being has a history of being treated with lurasidone.
18 . The method of claim 1 , wherein the human being has a history of being treated with olanzapine.
19 . The method of claim 1 , wherein the human being has a history of being treated with ziprasidone.
20 . The method of claim 1 , wherein the human being has a history of being treated with iloperidone.
21 . The method of claim 1 , wherein the human being has a history of being treated with pimavanserin.
22 . The method of claim 1 , wherein the human being has a history of being treated with quetiapine.
23 . The method of claim 1 , wherein the human being has a history of being treated with clozapine.
24 . The method of claim 1 , wherein the human being has a history of being treated with prochlorperazine.